$0.85
▼ $0.00
(-0.47%)
Vol 704K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$76.7M
ROE
-100.1%
Margin
-13549.5%
D/E
1.28
Beta
0.62
52W
$1–$7
Wall Street Consensus
16 analysts · Apr 20263
Strong Buy
5
Buy
8
Hold
0
Sell
0
Strong Sell
50.0%
Buy Rating
Price Chart
Similar Stocks
RCEL
AVITA Medical Inc
$105.2M
MCRB
Seres Therapeutics Inc
P/E 25.0
$134.6M
GOSS
Gossamer Bio Inc
$717.5M
HURA
TuHURA Biosciences Inc
$45.9M
ANIX
Anixa Biosciences Inc
$102.7M
FBIO
Fortress Biotech Inc
P/E 28.5
$113.6M
GANX
Gain Therapeutics Inc
$123.8M
INO
Inovio Pharmaceuticals Inc
$119.5M
SERA
Sera Prognostics Inc
$113.9M
Earnings
Beat rate: 60.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.19 | $-0.14 | +$0.05 |
| Sep 2025 | $-0.19 | $-0.26 | $-0.07 |
| Jun 2025 | $-0.19 | $-0.22 | $-0.03 |
| Mar 2025 | $-0.19 | $-0.17 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $190K | — |
| Net Income | — | -$15.0M | -$14.9M | -$19.5M | -$25.7M | -$14.0M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -93.5% | -93.5% | -93.5% | -93.5% | -100.1% | -100.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -4563.1% | -4563.1% | -4563.1% | -13549.5% | -13549.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 1.56 | 1.56 | 1.56 | 1.56 | 1.28 | 1.28 |
| Current Ratio | 5.63 | 5.63 | 5.63 | 5.63 | 5.93 | 5.93 |
Key Ratios
ROA (TTM)
-74.7%
P/S (TTM)
403.86
P/B
4.3
EPS (TTM)
$-0.83
52W High
$7.29
52W Low
$0.64
$0.64
52-Week Range
$7.29
Financial Health
Free Cash Flow
-$12.2M
Net Debt
$1.3M
Cash
$10.7M
Total Debt
$12.0M
As of Dec 31, 2025
How does ATYR compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ATYR valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
403.9
▲
3043%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
4.3
▲
76%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ATYR profitability vs Biotechnology peers
ROE
-100.1%
▼
49%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-13549.5%
▼
4625%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-74.7%
▼
60%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
ATYR financial health vs Biotechnology peers
D/E ratio
1.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
5.9
▲
34%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
0.6
▼
36%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ATYR fundamentals radar
ATYR
Peer median
Industry
ATYR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ATYR vs peers: key metrics
Latest News
No related news yet